Interesting thing - the company has a range of products for CNS diseases but all are pre-clinical except for one being filed for AD treatment approval.
With this - the market cap is $7.1 Billion
This gives AVXL great hope if the current trial results come good to very good - they can also trial for early approval.
One big difference, they have collaborations with 2 major pharma - ESAI and ABBV - that gives them much legitimacy
The study is ongoing. Enrollment was complete march 2021 and it is an 18 month study so last patient last visit will be September 2022 (maybe August). So results are unlikely before November 2022, probably December (CTAD is Nov 29-Dec 2 so may present there. Anavex should have additional data by then to present and to add to the TLD release around October)
Market Data 
Markets 
AI
